Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

52 patients that had previously participated in the RDBPC study of intralymphatic immunotherapy (ILIT) with 2 concomitant allergens, birch and grass, with NCT02423707, were eligible for an open follow up 5-6 years after treatment.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lars Olaf Cardell

Criteria

Inclusion Criteria:

• Moderate to severe allergic rhinitis to birch and grass pollen defined with a positive skin prick test and elevated allergen specific IgE antibodies

Exclusion Criteria:

• uncontrolled or perennial asthma

• other pulmonary disease

• known autoimmune or collagen disease

• chronic infection

• other significant disease

• severe atopic dermatitis

• use of beta blockers or angiotensin converting enzyme inhibitors as antihypertensive medications

• symptomatic sensitization to house dust mite or furry animals with daily exposure

• chronic upper airways disease

• pregnancy

• nursing

• obesity with BMI >30

• withdrawn informed consent